IGC Pharma Preliminary Preclinical Analyses Of TGR-63 Demonstrate Blood-Brain Barrier Permeability And Safety Profile And Shows No Adverse Effects

7/9/24 9:11:25 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IGC alert in real time by email

- Preliminary Analysis confirms the presence of TGR-63 in brain tissue and shows no adverse effects. -

IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced preclinical data demonstrating TGR-63's potential as an effective treatment for Alzheimer's disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer's murine models both indicate that TGR-63 has the potential to cross the blood-brain barrier in humans. These findings build on earlier results demonstrating TGR-63's efficacy in reducing amyloid plaque in Alzheimer's mouse models.

Get the next $IGC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IGC

Date	Price Target	Rating	Analyst

More analyst ratings

$IGC
Financials

Live finance-specific insights

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap
11/14/24 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Pharma Reports First Quarter Fiscal 2025 Results
IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp
8/8/24 9:30:00 PM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced positive interim results from its ongoing Phase 2 trial for IGC-AD1. The interim data have shown promising results in reducing Alzheimer's agitation, which is a major challenge for patients and their caregivers alike. This development marks a significant step forward in the fight against Alzheimer's and brings hope to millions of people affected by this devastating disease. In January 2024, the Company announced details about its dru
6/24/24 7:30:00 PM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o
1/21/25 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Announces Results of its 2024 Annual Stockholders Meeting
IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla
8/26/24 7:00:00 PM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (IHV), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Terry founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network (PanCAN), and the National
3/12/24 3:00:00 PM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care

$IGC
Press Releases

Fastest customizable press release news feed in the world

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o
1/21/25 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery. They will also discuss key upcoming milestones, including new clinical trial launches, preclinical developments, and efforts to broaden the Compa
1/13/25 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing
1/8/25 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care

IGC Pharma Preliminary Preclinical Analyses Of TGR-63 Demonstrate Blood-Brain Barrier Permeability And Safety Profile And Shows No Adverse Effects

Chat with this insight

Recent Analyst Ratings for
$IGC

$IGC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

$IGC
Financials

Live finance-specific insights

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

$IGC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by IGC Pharma Inc.

SEC Form SC 13D filed by IGC Pharma Inc.

$IGC
Leadership Updates

Live Leadership Updates

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

$IGC
Press Releases

Fastest customizable press release news feed in the world

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

$IGC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

Director Prins Richard K gifted 200,000 shares, decreasing direct ownership by 16% to 1,042,917 units (SEC Form 4)

Bradbury Strategic Investment Fund A (Cayman Islands Registration No. Cr-359857) was granted 8,823,529 shares, increasing direct ownership by 176% to 13,823,529 units (SEC Form 4)

$IGC
SEC Filings

SEC Form 10-Q filed by IGC Pharma Inc.

SEC Form 10-Q filed by IGC Pharma Inc.

IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

IGC Pharma Preliminary Preclinical Analyses Of TGR-63 Demonstrate Blood-Brain Barrier Permeability And Safety Profile And Shows No Adverse Effects

Chat with this insight

Recent Analyst Ratings for $IGC

$IGC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

$IGC Financials

Live finance-specific insights

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

$IGC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by IGC Pharma Inc.

SEC Form SC 13D filed by IGC Pharma Inc.

$IGC Leadership Updates

Live Leadership Updates

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

$IGC Press Releases

Fastest customizable press release news feed in the world

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

$IGC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

Director Prins Richard K gifted 200,000 shares, decreasing direct ownership by 16% to 1,042,917 units (SEC Form 4)

Bradbury Strategic Investment Fund A (Cayman Islands Registration No. Cr-359857) was granted 8,823,529 shares, increasing direct ownership by 176% to 13,823,529 units (SEC Form 4)

$IGC SEC Filings

SEC Form 10-Q filed by IGC Pharma Inc.

SEC Form 10-Q filed by IGC Pharma Inc.

IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Recent Analyst Ratings for
$IGC

$IGC
Insider Purchases

$IGC
Financials

$IGC
Large Ownership Changes

$IGC
Leadership Updates

$IGC
Press Releases

$IGC
Insider Trading

$IGC
SEC Filings